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ABSTRACT
Background: This study aims to report on the design of a model to determine the cost-effectiveness of
prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and
budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis
or with first episode psychosis (FEP).
Methods: PsyMod was built in parallel with the development of a new standard of care for treatment of
early psychosis in the Netherlands. PsyMod is a state-transition cohort simulation model and considers
six health states, namely ultra-high risk of psychosis (UHR), FEP, post-FEP, no-UHR, recovery/remission,
and death. Results are expressed as total healthcare costs, QALYs, incremental cost-effectiveness ratio
(ICER), and budget impact.
Results: PsyMod was used to extrapolate budget impact and cost-effectiveness of cognitive beha-
vioural therapy for preventing FEP for individuals at UHR of psychosis (CBTuhr) compared to care as
usual. CBTuhr resulted in a per-patient increase of 0.06 QALYs and a per patient cost reduction of €654
(dominant ICER) with a reduction in 5-year healthcare costs of €1,002,166.
Conclusions: PsyMod can be used to examine cost-effectiveness and budget impact of interventions
targeting prevention and treatment of FEP and is freely available for academic purposes upon request
by the authors.
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1. Introduction
Schizophrenia is among the world’s leading causes of disabil-
ity affecting the lives of patients (and their families) during the
critical years of adolescence and early adulthood [1–5]. Besides
having a negative impact on social life and work [6,7], schizo-
phrenia is associated with an increase in substance abuse,
depression, violence, and suicide attempts [7]. Consequently,
health-related and economic costs to patients, their families
and society are substantial [8,9] and go beyond direct medical
costs [10]. While the main driver of indirect costs seems to be
long-term unemployment [11], hospitalization alone may
account for up to 77% of the direct cost [12].
The high burden of schizophrenia spectrum and other
psychotic disorders (as it is formally defined in the
Diagnostic and Statistical Manual of Mental Disorders fifth
edition [13]) underscores the importance of early detection
and proactive intervention in patients at risk of a first psycho-
sis [14,15]. Likewise, delayed detection and treatment, result-
ing in longer duration of untreated psychosis (DUP), is
associated with poor outcomes [16–18]. The two main goals
of early intervention programmes are hence (1) to reduce the
DUP, and (2) to provide consistent and comprehensive care
throughout the most critical first years of the disorder [19]. In
recent years these programmes became more and more avail-
able with evidence suggesting their effectiveness and cost-
effectiveness [7,10,12,20–26].
Also regarding other elements of care for psychosis or schi-
zophrenia, a range of cost-effectiveness studies have been
performed. Several of these used health economic decision
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models, using various modelling techniques [27]. Most model-
based economic evaluations focused on pharmacological inter-
ventions in stages later than ‘ultra-high risk of psychosis’ (UHR)
or ‘first episode psychosis’ (FEP) [28–37]. Moreover, there is
currently no cost-effectiveness model available combining
pathways for patients with UHR and FEP in one model which
is useful to evaluate the simultaneous impact of various inter-
ventions targeting different stages of (the development of)
schizophrenia.
Therefore, we developed a new model, which was based on
McGorry et al.’s clinical staging model [38]. With the introduc-
tion of a clinical staging model of psychiatric disorders by
McGorry and colleagues [38], the potential to improve and
individualise treatment and timing of interventions increased.
Policy-makers are in need of reliable information on both costs
and health effects of current practices as well as alternatives to
enable well informed decisions [39]. McGorry’s model includes,
among others, the stages 1) ultra-high risk of psychosis; 2) first
episode of psychotic disorder; 3a) incomplete remission from
first episode; 3b) recurrence or relapse of psychotic disorder;
3c) multiple relapses; and 4) severe, persistent or unremitting
illness. Patients with UHR demonstrate certain levels of inten-
sity, severity and/or pathognomonic symptoms (e.g. a Global
Assessment of Functioning-score <70) [40]. The development
of this staging model in which the importance of identification
and treating patients at UHR for psychosis was emphasized,
boosted an interest in preventive psychiatry and it has been
demonstrated that early detection and intervention in people
at ultra-high risk of developing psychosis can be successful to
prevent or delay a first psychosis [40–42].
The goal of the current manuscript is therefore to present
a health-economic model to determine the cost-effectiveness
of prevention and treatment of early psychosis (named
PsyMod). PsyMod was developed in parallel with the develop-
ment of a new Standard of Care for psychosis in the
Netherlands. The model aims to estimate the long-term cost-
effectiveness of interventions targeting individuals at ultra-
high risk (UHR) of developing a first psychosis or those with
a current first episode psychosis (FEP). Here, we describe (1)
the process of developing a conceptual model, (2) the final
structure of the model, and (3) the parameters used to popu-
late the model. Finally, PsyMod will be illustrated by
evaluating the cost-effectiveness and budget impact of cogni-
tive behaviour therapy to prevent FEP in individuals at UHR.
2. Development of the model
2.1. Model design and structure
Using the clinical staging model from McGorry et al. [38], the
model was built in parallel with the development of
a multidisciplinary standard of care for treatment of early
psychosis in the Netherlands [43]. During a period of two
years, a group of healthcare providers (n = 10), patient (family)
representatives (n = 2), and researchers (n = 6) (hereafter:
guideline group, GG) came together at approximately six-
week intervals to develop a new guideline and to reflect on
the model. An iterative process was started to simplify the
conceptual model such that it could be supported with epi-
demiological evidence, while still maintaining a satisfying level
of face validity according to the experts. Epidemiological evi-
dence was gathered to guide this process by means of
a comprehensive quasi-systematic literature review in
PsycINFO® (see appendix 1).
After arriving at a simplified conceptual model, the next
step was to use available evidence from the literature either to
populate the model with regard to the epidemiology of the
onset and course of psychosis (e.g. transition parameters from
one health state to another), or to calibrate modelled epide-
miological outcomes (e.g. the ratio in prevalence between two
stages; see below). Lastly, a draft version of the model was
presented at a health economic study group conference
(lolaHESG 2015), in order to receive comments from indepen-
dent peers.
A flow-diagram regarding the involvement of expert opi-
nion during model development is found in appendix 2.
The disease progression model as defined by McGorry et al
[38], including the states 1b) ultra-high risk of psychosis; 2) first
episode of psychotic disorder; 3a) incomplete remission from first
episode; 3b) recurrence or relapse of psychotic disorder; 3c)
multiple relapses; and 4) severe, persistent or unremitting illness,
was simplified by combining the states 3a, 3b, 3c and 4 into
a single post-FEP state. This simplification was made as experts
deemed the epidemiological evidence-base to be insufficient
for providing reliable input on the transitions between these
states. Moreover, our aim was limited to developing a model
able to assess the cost-effectiveness of services targeting indi-
viduals at ultra-high risk of developing psychosis and with
a first episode of psychosis. In addition, we added a no-UHR
state to capture individuals who no longer have a risk-status of
developing a psychosis, a state representing recovery/remis-
sion, and a death state (see Figure 1).
In PsyMod, simulated patients will start in the UHR stage. In
the UHR stage, individuals can transition to either FEP, no-
UHR, or death. Once a transition to no-UHR has occurred,
patients remain in this state until the end of the time horizon
(or when they die). Similarly, once patients transfer to FEP,
a transition back to UHR is not possible. From FEP, patients
can only move to the post-FEP state or to remission/recovery.
A transition to death is always possible and death is an
absorbing end-state. In principle, only at one instance can
Article Highlights
● PsyMod is a methodologically sound model that can be used to
examine the cost-effectiveness and budget impact of interventions
targeting prevention and treatment of first episode of psychosis.
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PsyMod in which cognitive behaviour therapy for preventing FEP
for individuals at UHR of psychosis (CBTuhr) was compared to care
as usual (CAU) demonstrated that CBTuhr dominated CAU while
reducing total five-year (undiscounted) healthcare costs by
€1,002,166.
● PsyMod is freely available for academic purposes upon request by the
authors.
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individuals transition back and forth between two health
states in PsyMod. This is the case for the states of post-FEP
and remission/recovery.
Given the chronic character of the condition and as epide-
miological evidence regarding the incidence and prevalence
often reports time intervals of one year, it was chosen to set
the cycle length of the model accordingly. A time-horizon of
ten years was deemed long enough by the experts to capture
the costs and effects of interventions targeting either indivi-
duals at ultra-high risk of developing psychosis and interven-
tions targeting individuals with a first episode of psychosis. For
example, it has been demonstrated that almost all transition
from UHR to FEP occur within 10 years of entry to the clinic
[44]. The simulated cohorts starts at an age of 25 years (in line
with the mean age in Ising et al. [45]). The model was con-
structed such that both a five-year and ten-year time horizon
can be applied.
A health care system perspective was assumed due to
the paucity on evidence regarding societal costs. Future
outcomes were discounted at 4% (costs) and 1.5%
(effects), in accordance with the pertinent Dutch guideline
for pharmacoeconomic research [46]. Half-cycle correction
was applied [47]. All costs are expressed in 2018 Euros, by
indexing unit cost prices as reported in the Dutch guide-
line for economic evaluations [46] using the consumer
price index.
2.2. Model parameters
Data concerning transition rates between health states were
extracted from existing literature. Costs and quality of life
associated with each stage were based on the resource use
and utilities as observed in a recent Dutch UHR trial with
a four-year follow-up [45]. The 1-year incidence of psychosis
in the Netherlands was taken from estimates reported in the
Dutch Handbook of Early Psychosis [48].
Efforts made to validate the model were based on the
Assessment of the Validation Status of Health-Economic deci-
sion models (AdViSHe) questionnaire [49]. The conceptual
model was validated on face validity (by experts) and cross
validity testing (e.g. to other staging and health economic
models). Input data was validated based on face validity only
as model fit testing (e.g. using R2 statistics) was deemed not
applicable (i.e. no parameters of the model were based on
regression models). Validation of the results and assumptions
of the model was done by external expert review (i.e. the
Lowlands Health Economic Study Group), and in addition via
extreme value testing (e.g. to see whether any errors
occurred), and by checking whether the relative number of
patients in each cycle and state is consistent with empirical
evidence. Operational validity was assessed by face validity
(e.g. by asking experts whether model outcomes were within
a likely (or expected) range) and cross validation testing of
1b
UHR
2
FEP
3a-c, 4 =
post-FEP
Remission/
Recovery
   No Symptoms, 0, 1a =
   No-UHR
Death
Stage of no, mild, or 
non-specific symptoms
Stage of subclinical and 
clinical disorder
Stage of recovery or 
disability or death
Figure 1. Markov model ‘PsyMod’.
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model outcomes (e.g. check whether internal epidemiology
was consistent with previous research).
2.2.1. Transition probabilities
Transitions to death were based on general mortality statistics
in the Netherlands as reported by Statistics Netherlands [50]
(based on the age specific mean mortality rate of people in
the Netherlands) and excess mortality in individuals with psy-
chosis as reported by Saha et al. [3].
The expert panel deemed the meta-analysis of Fusar-Poli
et al. (2012) to be the most complete source of input on the
transitions up to FEP [51]. Fusar-Poli et al. (2012) conducted
a meta-analysis of transition rates in individuals at UHR. A total
of twenty-seven included studies comprised 2,502 patients
with a mean age of 19.9 years. Transition risks were reported
for the time points after six months, after one year, and after
two and three years.
Whereas the estimate of the one-year transition by Fusar-
poli et al. (2012) from UHR to FEP could be directly used as
a transition parameter in the Markov model, the transitions
between the model states before FEP (UHR to UHR; UHR to no-
UHR and no-UHR to no-UHR) had to be calibrated, such that
the two-year and three-year transitions reported by Fusar-Poli
et al. (2012) were approximated by the model, see Tables 1
and 2 for the parameter values and appendix 3 for additional
details.
Austin et al. (2013) was used as our main source of epide-
miological input from the states starting at FEP [52]. Austin
et al. (2013) reported on the disease progress of FEP patients
over a ten-year time-horizon in the Danish OPUS trial. OPUS
originally enrolled 496 individuals with first episode of psy-
chosis, and 304 (61%) participated in the 10-year follow-up.
The authors present prevalence rates of ‘recovery’, ‘symptom
remission’, ‘positive and/or negative symptoms’, and ‘institu-
tionalisation’ at two, five, and ten-year follow-up. Experts con-
sidered this study to be appropriate for epidemiological input,
as the long-term follow-up, together with the multi-year,
multi-state report on prevalence rates, resulted in a higher
internal consistency of the modelled epidemiology than the
use of multiple, different studies. The OPUS categories of
‘recovery’ and ‘symptom remission’ were considered to repre-
sent our model state remission/recovery, whereas the OPUS
Table 1. State dependent yearly transition probabilities, as the mortality rate is age dependent it is not presented in this table.
Clinical state
To (%)
no-UHR (SE) UHR (SE) FEP (SE)
Remission/
Recovery (SE) post-FEP (SE)
from no-UHR 100 (0.0) - - - -
UHR 44.65 (0.0157) 33.83 (0.0149) 21.52
(0.0130)
- -
FEP - - 20.00
(0.0126)
30.34
(0.0145)
49.66 (0.0158)
Remission/Recovery - - - 50.42
(0.0158)
49.58 (0.0158)
post-FEP - - - 35.00
(0.0151)
65.00 (0.0151)
Table 2. justification of epidemiology parameters.
Parameter Status Value Justification
General mortality Direct input 0.313% Statistics Netherlands [46]
Excess mortality (FEP and post-FEP) Direct input 1.38% Based on Saha et al. [3]
Transition UHR -> no-UHR Calibrated parameters 44.65% Estimated to calibrate incidence of psychosis outcomes after 2
and 3 years
Transition UHR -> UHR Calibrated parameters 33.52% Estimated to calibrate incidence of psychosis outcomes after 2
and 3 years
Incidence of psychosis at 2 years Outcomes used for
calibration
29.0% (vs 29.1% in Fusar Poli
at 2 years)
Compared to Fusar Poli et al (2012) [47]
Incidence of psychosis at 3 years Outcomes used for
calibration
32.5% (vs 31.5% in Fusar Poli
at 3 years)
Compared to Fusar Poli et al (2012) [47]
Transition UHR -> FEP Direct input 21.52% Taken from Fusar Poli et al (2012), corrected for mortality [47]
Transition FEP -> FEP Calibrated parameters 20% Assumption: experts estimate that after two years most first
episodes will be over
Transition FEP -> remission/recovery Direct input 28.96% Based on Austin et al (2013) [48]
Transition FEP -> post-FEP Direct input 49.66% Based on Austin et al (2013) [48]
Transition remission/recovery ->
remission/recovery
Calibrated parameters 50.11% Estimated to calibrate the ratios remission/recovery vs post-
FEP
Transition remission/recovery -> post-
FEP
Calibrated parameters 49.58% Estimated to calibrate the ratios remission/recovery vs post-
FEP
Transition post-FEP -> post-FEP Calibrated parameters 63.62% Estimated to calibrate the ratios remission/recovery vs post-
FEP
Transition post-FEP -> remission/
recovery
Calibrated parameters 35.00% Estimated to calibrate the ratios remission/recovery vs post-
FEP
Ratio remission/recovery vs post-FEP
after 2 years
Outcomes used for
calibration
41:59 (vs 39:61 in Austin et al
(2013))
Compared to Austin et al (2013) [48]
Ratio remission/recovery vs post-FEP
after 5 years
Outcomes used for
calibration
42:58 (vs 45:55 in Austin et al
(2013))
Compared to Austin et al (2013) [48]
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categories ‘positive and/or negative symptoms’ and ‘institutio-
nalisation’ were interpreted as representing our model state
post-FEP. Tables 1 and 2 and appendix 3 provide more details
on the model transitions derived from Austin et al. (2013) [52].
The resulting estimates were also validated using a more
recent meta-analysis of Fusar-poli et al. 2016 [53]. This meta-
analysis was used for validation purposes only as it does not
provide information regarding health states other than FEP
and the prevalence of FEP for various points in time. In this
meta-analysis, the risk of a recurrence after FEP was estimated
to be 0.42 (95%CI: 0.30–0.54), 0.78 (95%CI: 0.58–0.93), and 0.84
(95%CI: 0.70–0.94) after one, two, and three years’ post-FEP
respectively. This was in line with the estimates calculated in
PsyMod (0.50, 0.74, 0.86).
2.2.2. Modelled epidemiology
Next, we estimated the required size of the simulated popula-
tion to be in line with Dutch epidemiology in order to esti-
mate the cost-effectiveness and total budget impact. In
a given year, approximately 3,000 people in the Netherlands
develop a FEP [48]. Furthermore, Fusar-poli et al. (2012) esti-
mated the transition probability from UHR to FEP to be 35.8%
[51]. This would mean that in the Netherlands, there are
approximately 3,000/0.358 = 8,330 new UHR patients annually
(assuming every person with FEP would first be UHR).
However, interventions targeting UHR can only be offered to
people already in the mental health system (because other-
wise they could not be screened for UHR). It is estimated that
approximately 30% of the UHR patients are currently in the
mental health system [54]. Hence, the estimated size of the
simulated cohort was 8,330 * 0.3 = 2,514. The absolute num-
ber of individuals from one yearly cohort of people with UHR,
combined with the transition matrix presented in Table 1,
results in the modelled disease progression for this cohort
over a time-horizon of ten years as depicted in Figure 2.
Table 2 provides an overview of the input and output
regarding the epidemiology, divided in parameters that were
taken straight from the literature (direct input), parameters
that were used to calibrate the epidemiology (calibrated para-
meters) and output from the model that could be compared
with outputs observed in literature (outcomes used for cali-
bration). The use of these three types of parameters was
necessary 1) as not all parameters could be directly observed
in literature; and 2) to make sure that model outcomes are in
line with existing literature. The process of calibration is
explained in more detail in appendix 3.
2.3. Measurement and valuation of costs and health
effects
The multicentre trial conducted in the Netherlands by Ising
et al. [12,45] was selected by experts to provide input on the
cost and quality of life estimates of the different states in the
model. Ising et al. [12,45] provide input on the four-year costs
and quality of life of people at ultra-high risk of developing
psychosis receiving usual care. As a part of the trial-population
developed a first episode of psychosis, these four-year cost
and quality of life data could be used to estimate the costs
and quality of life associated with the different states in the
model.
In order to estimate health care costs and utilities for each
health state, the trial data was categorized according to the
following assumptions:
● For UHR: mean costs and utilities of patient in the first
two years of the trial who did not develop FEP.
● For no-UHR: mean costs and utilities of patients in the
third and fourth year of the trial who did not develop
FEP. One should keep in mind that these are still people
with minor to moderate mental problems.
● For FEP: mean costs and utilities of patients in the first
two years after FEP.
● For Remission/recovery: assumed to be equal to no-UHR
+ €1,000 (before indexing to 2018; based on clinical
opinion). This assumption was made as it was considered
that patients in the remission/recovery state were con-
sidered to use slightly more health care sources com-
pared to no-UHR.
● Post-FEP: mean costs and utilities of patients in the third
and fourth year after FEP, excluding cost and utilities for
those in remission/recovery.
Table 3 presents cost and utility estimates per health state in
care as usual based on Ising et al. (2016) The associated
resource use costs can be found in the online supplement of
Ising et al. (2016) [45], and have been adapted as mentioned
above to fit the health states of the model. The costs pre-
sented below also include costs of treatments included in care
as usual which were defined in accordance with the Dutch
clinical guidelines (see below).
2.4. Interventions included in the base case (care as
usual)
Care as usual was defined based on Dutch clinical guidelines.
Experts estimated that care as usual required three treatments
for patients with FEP: 1) medication (to 100% of the patients);
2) CBT focusing on patients with FEP (to 50% of the patients);
and 3) family intervention (to 5% of the patients). Moreover, in
care as usual, no interventions are offered to UHR patients
(except for treatments they are receiving for other than UHR).
2.5. Model output
Results in PsyMod are expressed as total healthcare costs,
QALYs, life years per scenario (i.e. base case or alternative
scenario), and budget impact. The incremental cost-
effectiveness ratio (ICER) is then calculated as follows:
(Costsalternative – Costsbase case)/(QALYsalternative –
QALYsbase case). This way, the ICER represents the incremental
costs per QALY gained.
2.5.1. Probabilistic sensitivity analysis
Parameter uncertainty is examined in the model through
probabilistic sensitivity analysis. We characterise uncertain
parameters (i.e. all input parameters in the model) by using
probability distributions (e.g. normal distribution or beta
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distribution). As utility values are bound between 0 to 1, the
beta distribution was used for these parameters. Transition
probabilities are also bound between 0 and 1, but transitions
coming from one health state should sum to 1 (e.g. otherwise
you would lose/gain ‘patients’ moving from these health
states). Hence, the Dirichlet distribution was used, which is
basically a multivariate beta distribution. To capture uncer-
tainty around the costs associated with each health state,
the gamma distribution was used. After assigning distributions
to all parameters, the model was re-run 1,000 times in which
each time a random draw from the parameter distributions for
every parameter was taken, leading to 1,000 ICERs. Next, all
1,000 simulations were plotted on a cost-effectiveness plane
(CE-plane) to capture the uncertainty in the ICER estimate.
Finally, a cost-effectiveness acceptability curve is constructed
for the costs per QALY gained in which the likelihood that the
alternative scenario is cost-effective is presented given differ-
ent willingness-to-pay thresholds.
3. Results of model testing
To apply PsyMod to a real-world example, we extrapolated the
results of a trial-based economic evaluation of Ising et al.
(2016) in which the cost-effectiveness of cognitive behaviour
therapy for preventing first-episode psychosis for individuals
at UHR of psychosis (CBTuhr) [45]. This study demonstrated
that CBTuhr resulted in a significantly lower proportion of
transitions to psychosis compared to care as usual (with
a risk difference of 0.122). Moreover, the intervention cost of
CBTuhr was estimated to be €1,924 per patient. In the here
presented application of PsyMod, CBTuhr (and the corre-
sponding cost and effect parameters) was added to the
model as a ‘new’ intervention at an arbitrary coverage rate
of 25% and compared to care as usual. In addition, the ten-
year cost-effectiveness and five-year budget impact of adding
CBTuht to care as usual was examined using PsyMod (in
accordance with the Dutch guidelines for budged impact
and economic evaluations) [46].
Running the model with these scenarios resulted in the
cost-effectiveness plane and CEAC as presented in Figure 3a
& 3b. On average, adding CBTuhr to care as usual resulted in
a per-patient increase of 0.06 QALYs and a per-patient cost
reduction of €654 over a ten-year time horizon resulting in
a dominant ICER. On a national level, looking at the budget
impact, the implementation of CBTuhr would reduce total
five-year (undiscounted) healthcare costs by €1,002,166 indi-
cating that the required intervention costs of € 1.2 million are
more than offset. For the first five years, yearly savings are:
€161,154; €208,556; €214,245; €213,400; and €204,812
respectively (undiscounted, in accordance with Dutch guide-
lines [46]).
4. Discussion
PsyMod is the first model developed with the potential to
assess the cost-effectiveness of competing interventions target-
ing UHR and FEP. Models are a useful tool to simulate real-world
situations and can provide valuable insights for policymakers
on how to optimally allocate available resources. However, all
simulation approaches are based on assumptions. In our paper,
we aimed to be transparent about the assumptions underlying
PsyMod, such that users can form a good judgement on the
validity and usefulness of its results. Results of PsyMod were
compared to clinical studies and calibrated in such a way that
they correspond with observed epidemiology. Moreover,
PsyMod was used to extrapolate findings of the cost-
effectiveness of CBTuhr and showed that CBTuhr is likely to
be a promising intervention on the long-term in terms of cost-
effectiveness. One should keep in mind, however, that in this
analysis the costs of identifying persons at UHR were not
considered.
Albeit similar models do not exist, health economic model-
ling has been used in the past to examine treatment effects
for schizophrenia or psychosis specifically. For example,
Valmaggia et al. [36] employed a simple decision tree model
(i.e. only looking at ‘transition to psychosis’ or ‘no transition’)
to evaluate the effects of Outreach and Support in South
London, an early intervention in people at high risk of psy-
chosis. They concluded that services that permit early detec-
tion of people at high risk of psychosis may be cost saving.
Next, McCrone et al. [32] used a Markov model to examine the
effects of early intervention services on service costs for peo-
ple with first-episode psychosis. Instead of using health states,
the model was constructed to map care pathways. Again, early
intervention was demonstrated to be cost saving.
Most of the currently available health economic models
focus solely on antipsychotics with a variety of health states
ranging from symptomatic health states (e.g. remission/no
remission [55–57];) to adverse events only [58,59]. For example,
a study of Perlis et al. [57] examined the cost-effectiveness of
a genetic test that may identify individuals with greater like-
lihood of responding to clozapine treatment for schizophrenia
and focused on ‘recovered from psychosis’, or ‘psychosis’ [57].
Palmer et al. [55,56] examined the cost-effectiveness of three
antipsychotic treatments for people with schizophrenia using
a Markov model. Albeit being technically slightly different to
more recent Markov models, this model focused on sympto-
matic health states, i.e. ‘positive & negative syndromes’, ‘nega-
tive syndromes only’, ‘positive syndromes only’, ‘no positive &
no negative syndromes’, ‘suicide’, and ‘death’.
Several strengths and limitations apply to our modelling
approach. By closely working together with a group of experts
in the field of early psychosis, we increased the clinical rele-
vance of our model. Likewise, by presenting a draft version of
the model at a health economic study group conference
(lolaHESG 2015), we were able to integrate expert opinion
on our assumptions from an early state on and from an
Table 3. costs and utilities associated with each state.
Costs (in €; 2018) Utility value
no-UHR € 3,970 (SD: €36) 0.756 (SD: 0.014)
UHR € 4,874 (SD: €191) 0.640 (SD: 0.015)
FEP € 7,200 (SD: €190) 0.366 (SD: 0.015)
Remission/recovery € 5,019 (SD: €114) 0.756 (SD: 0.014)
Post-FEP € 8,452 (SD: €163) 0.362 (SD: 0.015)
Death € 0 0
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interdisciplinary perspective. PsyMod incorporates evidence
from a range of different input sources. Epidemiological evi-
dence on transition rates was complemented with clinical
expert opinion. Furthermore, costs and health utilities were
derived from an RCT with long follow-up [12]. At first glance,
a Dutch study looking at costs of antipsychotic medication,
psychiatric and somatic health care for patients estimated
vastly higher annual costs compared to the estimates used
in PsyMod [60]. However, this study was conducted in sub-
stantially older patients, based on claims data, and did not
follow a cohort approach (only a snapshot in time and hence
a relatively high number of patients with long-term care).
Finally, PsyMod was partly validated using the AdviSHE tool
(i.e. not all items from the AdviSHE tool could be covered).
Several other limitations need to be acknowledged. Empirical
evidence in our model is based on a limited number of
sources. Available evidence on UHR and FEP regarding pre-
valence and long-term implications is scarce. In addition,
a number of original studies that could have been useful to
inform our model were either conducted with small sample
sizes (i.e. smaller than 100 participants), or did not cover the
stages of interest in our model [61,62]. Therefore, we chose to
base our assumptions on a limited number of relevant pub-
lications, complemented with expert opinion. Further, PsyMod
was constructed from a Dutch perspective. No direct conclu-
sions can be drawn about its applicability to other countries.
Moreover, given the lack of accurate data on societal costs,
PsyMod incorporates health care costs only and thus solely
provides a health care perspective. The choice for a cohort
Markov model automatically implies that we did not model
individual patient characteristics (in contrast to taking a micro-
simulation approach) and that transition probabilities between
states were assumed to be stable over time. However, a more
individual patient-oriented simulation, e.g., a micro-simulation,
requires substantially more information to construct the
model which was not available. The stages severe, persistent
or unremitting illness as outlined in McGorry et al. [38], were
simplified by combining these into a single post-FEP state.
This simplification was justified by the fact that experts
deemed the epidemiological evidence-base to be insufficient
for providing reliable input on the transitions between these
states, but might bias our result (e.g. by resulting in less
extreme cases by merging states). Lastly, all simulated patients
start in the UHR state, which implicitly assumes that every
individual developing FEP qualifies for UHR first. In reality, it
is likely that several phenotypic pathways leading to FEP exists
outside of the UHR paradigm (e.g. in patients in which early
psychotic symptoms may be absent) [40,63]. Furthermore, if
a proportion of the UHR patients is not detected this would
mean a reduction in the demonstrated benefits. When extra-
polating the results for CBTuhr using PsyMod, we have
accounted for this by assuming a non-optimal coverage rate
(i.e. 25%).
4.1. Conclusion
PsyMod is the result of a comprehensive modelling exercise
and can be used to examine the cost-effectiveness and budget
impact of interventions targeting prevention and treatment of
first episode of psychosis. PsyMod can be used for various
interventions (e.g. medication, cognitive behaviour therapy,
et cetera) in a relatively easy and accessible way. Moreover,
PsyMod is freely available for academic purposes upon request
from the authors. PsyMod may stimulate the generation and
uptake of cost-effectiveness evidence and thereby help to
increase efficiency of mental health care, particularly in the
Netherlands. Further research should examine the transferabil-
ity of the results provided by the model to other countries and
to determine what changes may be necessary to make the
model applicable to other settings.
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